染色体检查发现异常染色体t(8;21),基因检测发现AML1-ETO(RUNX1-RUNX1T1)融合基因,诊断急性髓细胞白血病(AML)伴AML1-ETO融合基因,标准IA方案诱导治疗一疗程缓解,基因突变报告提示未见c-KIT突变,危险分组为低危组,继续氟达拉滨联合阿糖胞苷巩固治疗,一疗程后复查基因转为阴性;该患者继续巩固治疗4疗程结束治疗。
你的孩子AML1-ETO基因(现在更新命名为:RUNX1-RUNX1T1基因),就这个基因本身而言,它的预后是相对好的,首选化疗,不得已才考虑做骨髓移植。我们科研究统计过这种基因阳性病例的五年生存率能到70-80%以上,但有些其他因素还会对预后产生影响,比如:孩子发病时的年龄,ETO基因下降的速度,c-KIT突变,有没有合并其他异常染...
AML1-ETO是一种融合基因，它在急性髓细胞性白血病（AML）中发挥作用。这种融合基因是由一个被称为RUNX1或AML1的基因与另一个名为ETO或RUNX1T1的基因相互融合而产生的。AML1-ETO融合基因在急性髓细胞性白血病中的某些亚型中发现，特别是在M2亚型中。拷贝值1750000可能表示AML1-ETO融合基因的数量。在分...
PaulLiu. (2010) RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1). Journal of Cellular Biochemistry 110 :10.1002/jcb.v110:5, 1039-1045 /Hyde RK, Liu PP. RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes...
The AML1-ETO (RUNX1-RUNX1T1) fusion gene created by the chromosome translocation t(8;21) (q21;q22) is one of the essential contributors to leukemogenesis. Only a few studies in the literature have focused on fusion gene-derived circular RNAs (f-circRNAs). Here, we report several AML1-...
Hybridization position of the probes on the chromosome. Self-Attestation Abnova self-attests to comply with the U.S. Framework for Nucleic Acid Synthesis Screening Applications Gene Info — RUNX1 Gene Info — RUNX1T1 Interactomes Pathways Diseases...
Treatment failure resulting from disease relapse in AML, including AML1-ETO (AE) (also known as RUNX1-RUNX1T1) (+) AML, remains a challenge [2]. Developing more sensitive MRD detection methods might improve current treatment strategies and prevent relapse. For AML with fusion genes, the ...
Development of t(8;21)and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia:additional evidence for multiple steps involved in disease progression[J]. Cancer Genet, 2011,204(3):165-170. DOI: 10.1016/j.cancergencyto.2010.09.001 . 返回引文位置...
The translocation t(8;21)(q22;q22), which results in the fusion of the AML1 (RUNX1) and ETO (CBFA2T1) genes, is a recurrent aberration in acute myeloid leukemia (AML), preferentially correlated with FAB M2, and has the highest incidence in childhood AML. Because of the favorable ...
MRD monitoring of RUNX1-RUNX1T1 transcript was assessed with quantitative polymerase chain reaction. After two cycles of consolidation, patients received risk stratification treatment as follow. Low risk (LR) group (C-KIT-ASXL1- with main molecular response (MMR)) was recommended to chemotherapy ...